Payment overview · 2025
General Payments
$1,009.29
42 reported records · 14 companies
Healthcare provider profile · identity verified
Damaso Alberto Maresma
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · CAPE CORAL, FL · NPI 1932845609
Verified facts
What the public records show
CMS Open Payments records show Damaso Alberto Maresma received $1,009.29 in general payments during 2025 across 42 reported records.
Sumitomo Pharma America, Inc. accounted for 24.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $249.63 | 24.7% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $136.38 | 13.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $128.81 | 12.8% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $114.03 | 11.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $69.75 | 6.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.91 | 5.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $47.70 | 4.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.19 | 4.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.30 | 3.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $37.28 | 3.7% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $31.10 | 3.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.32 | 2.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.02 | 2.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $18.87 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,009.29 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $249.63 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $128.81 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $104.43 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $104.43 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $104.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $91.57 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $87.74 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $69.75 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $69.75 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.91 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.91 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $47.70 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $40.19 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $38.30 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $37.28 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $31.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 175 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 125 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 28 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | 16 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
175 | 63 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
125 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
125 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
120 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 481 | 203 |
| Diclofenac Sodium | Diclofenac Sodium | 471 | 154 |
| Metformin Hcl | Metformin Hcl | 382 | 158 |
| Amlodipine Besylate | Amlodipine Besylate | 377 | 160 |
| Losartan Potassium | Losartan Potassium | 334 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 308 | 125 |
| Lisinopril | Lisinopril | 279 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 249 | 98 |
| Gabapentin | Gabapentin | 232 | 111 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 100 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 195 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 194 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 182 | 70 |
| Omeprazole | Omeprazole | 180 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 80 |
| Farxiga | Dapagliflozin Propanediol | 175 | 63 |
| Alcohol Pads | Alcohol Antiseptic Pads | 159 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 65 |
| Alendronate Sodium | Alendronate Sodium | 127 | 42 |
| Jardiance | Empagliflozin | 125 | 43 |
| Furosemide | Furosemide | 123 | 55 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 122 | 51 |
| Pioglitazone Hcl | Pioglitazone Hcl | 121 | 45 |
| Eliquis | Apixaban | 120 | 40 |
| Montelukast Sodium | Montelukast Sodium | 119 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 115 | 46 |
| Mometasone Furoate | Mometasone Furoate | 110 | 29 |
| Simvastatin | Simvastatin | 110 | 44 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 34 |
| Methocarbamol | Methocarbamol | 109 | 64 |
| Atenolol | Atenolol | 97 | 32 |
| Meclizine Hcl | Meclizine Hcl | 90 | 47 |
| Torsemide | Torsemide | 89 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 32 |
| Famotidine | Famotidine | 85 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 35 |
| Meloxicam | Meloxicam | 77 | 39 |
| Ammonium Lactate | Ammonium Lactate | 75 | 37 |
| Fenofibrate | Fenofibrate | 75 | 34 |
| Clobetasol Propionate | Clobetasol Propionate | 73 | 32 |
| Ketoconazole | Ketoconazole | 72 | 31 |
| Tramadol Hcl | Tramadol Hcl | 69 | 28 |
| Carvedilol | Carvedilol | 65 | 29 |
| Chlorthalidone | Chlorthalidone | 64 | 31 |
| Allopurinol | Allopurinol | 63 | 22 |
| Enalapril Maleate | Enalapril Maleate | 63 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 22 |
| Nifedipine Er | Nifedipine | 63 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 54 |
| Sertraline Hcl | Sertraline Hcl | 62 | 32 |
| Glyxambi | Empagliflozin/Linagliptin | 60 | 15 |
| Ibuprofen | Ibuprofen | 60 | 35 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 56 | 27 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 54 | 27 |
| Diclofenac Potassium | Diclofenac Potassium | 54 | 32 |
| Rabeprazole Sodium | Rabeprazole Sodium | 52 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 30 |
| Azithromycin | Azithromycin | 49 | 47 |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 49 | 19 |
| Trazodone Hcl | Trazodone Hcl | 49 | 21 |
| Metoclopramide Hcl | Metoclopramide Hcl | 48 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 18 |
| Donepezil Hcl | Donepezil Hcl | 47 | 20 |
| Risedronate Sodium | Risedronate Sodium | 47 | 21 |
| Finasteride | Finasteride | 45 | 19 |
| Sucralfate | Sucralfate | 44 | 16 |
| Nitroglycerin | Nitroglycerin | 42 | 22 |
| Spironolactone | Spironolactone | 42 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 17 |
| Alprazolam | Alprazolam | 41 | 17 |
| Baclofen | Baclofen | 41 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 24 |
| Xarelto | Rivaroxaban | 41 | 14 |
| Nystatin | Nystatin | 40 | 16 |
| Megestrol Acetate | Megestrol Acetate | 39 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 37 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | 14 |
| Dapagliflozin | Dapagliflozin Propanediol | 35 | 31 |
| Glimepiride | Glimepiride | 35 | 17 |
| Levofloxacin | Levofloxacin | 35 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 17 |
| Prednisone | Prednisone | 32 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | 12 |
| Ozempic | Semaglutide | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 15 |
| Lactulose | Lactulose | 29 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Pentoxifylline | Pentoxifylline | 29 | 11 |
| Januvia | Sitagliptin Phosphate | 28 | 11 |
| Linzess | Linaclotide | 28 | 16 |
| Mirtazapine | Mirtazapine | 28 | 13 |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 26 | 11 |
| Latanoprost | Latanoprost | 26 | 11 |
| Ciclopirox | Ciclopirox | 25 | 11 |
| Potassium Chloride | Potassium Chloride | 25 | 14 |
| Mupirocin | Mupirocin | 24 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Naproxen | Naproxen | 23 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 23 | suppressed |
| Temazepam | Temazepam | 22 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Metronidazole | Metronidazole | 17 | 11 |
| Mupirocin | Mupirocin Calcium | 17 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Prolia | Denosumab | 16 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Zafirlukast | Zafirlukast | 15 | suppressed |
| Acarbose | Acarbose | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 14 |
| Telmisartan | Telmisartan | 14 | suppressed |
| Travoprost | Travoprost | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | 12 |
| Topiramate | Topiramate | 13 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Cilostazol | Cilostazol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,009.29 · 42 records | Sumitomo Pharma America, Inc. | AIRSUPRA, APTIMA, BREZTRI, CREON, EVENITY, FARXIGA, GEMTESA, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, VERQUVO, VOQUEZNA, ZAVZPRET, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error